Switching to Tresiba(R) Benefits People with Diabetes Irrespective of Blood Sugar Levels in a Real-world Setting

PR71391

BAGSVAERD, Denmark, Dec. 5, 2017 /PRNewswire=KYODO JBN/ --

- Switching to Tresiba(R) reduced the rate of hypoglycaemia by 67% in people

with controlled blood sugar levels   

- In people with diabetes whose blood sugar was too high, switching to

Tresiba(R) significantly improved blood sugar levels   

Switching to Tresiba(R) from another basal insulin benefits people with

diabetes regardless of whether or not their blood sugar levels are

controlled.[1] This is the conclusion of a post-hoc analysis of data from the

EU-TREAT study collected in a real-world clinical setting among people with

type 1 and type 2 diabetes.

In people with type 2 diabetes whose blood sugar levels were controlled (HbA1c

Equal to or Less than 7.5%) with basal insulin prior to switching, Tresiba(R)

significantly reduced the rate of hypoglycaemia (low blood sugar levels) while

maintaining blood sugar control. Results showed a 67% reduction in the rate of

hypoglycaemic events over six months after switching to Tresiba(R), with an 11%

lower dose of insulin.[1]

In patients with uncontrolled type 1 or type 2 diabetes, switching to

Tresiba(R) resulted in significantly improved glycaemic control without an

increase in the risk of hypoglycaemia or insulin dose.[1][2] These results were

sustained for up to 12 months after switching from another basal insulin,

mainly insulin glargine U100 and insulin detemir.[1]

In people with type 1 diabetes whose blood sugar levels were controlled, a 16%

lower rate of hypoglycaemia was observed over six months, and blood sugar

control was maintained with a 13% lower dose of insulin.[1]  

"This new analysis shows that people with diabetes who have switched to

Tresiba(R) in the real world benefit from this change, regardless of whether

they did so to improve blood glucose control or reduce the risk of

hypoglycaemia," said Mads Krogsgaard Thomsen, executive vice president and

chief science officer at Novo Nordisk. "This confirms that the benefits of

Tresiba(R) seen in clinical trials are being reproduced in clinical practice."

The main results of the EU-TREAT real-world evidence study reported earlier

this year showed that that people with type 1 and type 2 diabetes experienced a

significant reduction in HbA1c six months after switching to Tresiba(R). Rates

of overall hypoglycaemia were also significantly lower at six months after

switching to Tresiba(R). In people with type 1 diabetes, the rate of severe

hypoglycaemia was reduced by 85% and by 92% in people with type 2 diabetes.

Similar reductions were seen at 12 months.[2,3]

About EU-TREAT  

EU-TREAT (EUropean TREsiba AudiT) is a European, multicentre, real-world

evidence study (n=2,550) investigating the effect of switching to Tresiba(R)

from another basal insulin in people with type 1 (n=1,717) and type 2 (n=833)

diabetes. Patients in Austria, Denmark, Germany, Greece, Italy and Switzerland

were switched from another basal insulin to Tresiba(R) 6 months prior to data

collection. Outcome measurements were collected at 6±3 and 12±3 months after

initiation on Tresiba(R)and was compared to baseline measurement taken from the

prior basal insulin during a 3-month period prior to initiation on Tresiba(R).

[2,3]

About Tresiba[(R)]

Tresiba(R) (insulin degludec) is a once-daily basal insulin that provides a

duration of action beyond 42 hours with a flat and stable glucose-lowering

effect.[4,5] It provides low variability in blood glucose levels and a lower

risk of overall, nocturnal and severe hypoglycaemia vs. insulin glargine

U100.[4,6]  On occasions when administration at the same time of day is not

possible, Tresiba(R) allows for flexibility in day-to-day dosing time with a

minimum of eight hours between injections.[5] Tresiba(R) received its first

regulatory approval in September 2012 and has since been approved in more than

80 countries globally. It is now commercially available in more than 50

countries.

About Novo Nordisk  

Novo Nordisk is a global healthcare company with more than 90 years of

innovation and leadership in diabetes care. This heritage has given us

experience and capabilities that also enable us to help people defeat obesity,

haemophilia, growth disorders and other serious chronic diseases. Headquartered

in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries

and markets its products in more than 165 countries. For more information,

visit novonordisk.com [https://www.novonordisk.com/], Facebook

[https://www.facebook.com/novonordisk], Twitter

[https://mobile.twitter.com/novonordisk], LinkedIn

[https://www.linkedin.com/company/novo-nordisk], YouTube

[https://www.youtube.com/user/novonordisk/custom].  

Further information  

Media:

Katrine Sperling          +45-4442-6718    krsp@novonordisk.com

Åsa Josefsson             +45-3079-7708    aajf@novonordisk.com

Investors:

Peter Hugreffe Ankersen   +45-3075-9085    phak@novonordisk.com

Hanna Ogren               +45-3079-8519    haoe@novonordisk.com  

Anders Mikkelsen          +45-3079-4461    armk@novonordisk.com

Christina Kjær            +45-3079-3009    cnje@novonordisk.com  

Kasper Veje (US)          +1-609-235-8567  kpvj@novonordisk.com  

References  

1.    Novo Nordisk. EU-TREAT post hoc analysis. Data on file. 2017.  

2.    Siegmund T, Tentolouris N, Knudsen TS, et al. EU-TREAT 1: Switching to

insulin degludec reduces the risk of hypoglycaemia in patients with T1DM in a

real-world setting. Poster presentation. 77th Annual Scientific Sessions of the

American Diabetes Association (ADA), San Diego, California, US. June 2017.  

3.    Schultes B, Tentolouris N, Knudsen TS, et al. EU-TREAT 2: Switching to

insulin degludec improves glycaemic control in patients with T2DM in a

real-world setting. Poster presentation. 77th Annual Scientific Sessions of the

American Diabetes Association (ADA), San Diego, California, US. June 2017.   

4.    EMA. Tresiba(R) Summary of Product Characteristics. Available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf.

Last accessed: December 2017.  

5.    Haahr H, Heise T. A review of the pharmacological properties of insulin

degludec and their clinical relevance. Clin Pharmacokinet. 2014; 53:787-800.   

6.    Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec

versus glargine in type 2 diabetes. N Engl J Med. 2017; 377:723-732.

ZINC ID: HQMMA/TB/0917/0327: December 2017

SOURCE: Novo Nordisk